Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.38 |
| ▸ | ENTPD1 | P49961 | 2/20 | 0.38 |
| ▸ | DTYMK | P23919 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22327013 | 0.92 | ENTPD1 (0.38) | CA2P2RX3P2RX1P2RX2P2RX4 | |
| SCHEMBL16152184 | 0.84 | POLB (0.42) | CA2P2RX3P2RX1P2RX2DTYMK | |
| SCHEMBL13554396 | 0.84 | POLB (0.42) | CA2P2RX3P2RX1P2RX2DTYMK | |
| SCHEMBL22815044 | 0.84 | P2RX3 (0.43) | CA2P2RX3P2RX1P2RX2P2RX4 | |
| SCHEMBL26068620 | 0.82 | CA2 (0.45) | CA2 | |
| SCHEMBL22327030 | 0.82 | P2RX3 (0.43) | P2RX3P2RX1P2RX2P2RX4DTYMK | |
| SCHEMBL26068417 | 0.82 | P2RX3 (0.43) | P2RX3P2RX1P2RX2P2RX4DTYMK | |
| SCHEMBL22327257 | 0.82 | P2RX3 (0.43) | P2RX3P2RX1P2RX2P2RX4DTYMK | |
| SCHEMBL24971484 | 0.82 | FUT5 (0.39) | POLB | |
| SCHEMBL17254858 | 0.82 | POLB (0.38) | CA2P2RX3P2RX1P2RX2P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | CA2 4091/4885P2RX3 1119/4885P2RX1 1289/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | CA2 4091/4885P2RX3 1119/4885P2RX1 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.